Infection Risk among HS Patients Compared to Psoriasis: JAMA

Published On 2025-09-01 15:15 GMT   |   Update On 2025-09-01 15:15 GMT
Advertisement

Adults with moderate to severe hidradenitis suppurativa (HS) treated with adalimumab face a significantly higher risk of serious infections compared to those with psoriasis, according to a new cohort study published in JAMA Dermatology. Researchers analyzed U.S. insurance claims data of 10,349 adults initiating adalimumab between 2017–2020—1,650 with HS and 8,699 with psoriasis. They found that the HS group had a 53% higher hazard of hospitalization for noncutaneous infections (HR 1.53; 95% CI 1.34–1.86) after adjusting for confounders. Rates of sepsis (IRR 2.07; 95% CI 1.35–3.12) and genitourinary infections (IRR 2.22; 95% CI 1.22–3.86) were more than double in the HS cohort. HS patients also had a 28% higher odds of prolonged hospital stays (OR 1.28; 95% CI 1.13–1.45). Notably, HS patients were younger (mean age 36.2 vs. 46.5 years), more often female (77% vs. 50%), and had higher rates of obesity, Crohn’s disease, anxiety, and depression. The findings suggest that HS patients face a distinct infectious risk profile under immunosuppressive therapy compared to those with psoriasis. Researchers highlight the need for further studies to understand how disease severity, treatment regimens, and preventive strategies could mitigate this elevated infection risk. Until then, clinicians should remain vigilant when managing HS patients with adalimumab and consider close monitoring and tailored infection-prevention strategies.

Reference:
Wafae, B. G. d. O., Charrow, A. P., Stein, D., Barbieri, J. S., & Noe, M. H. (2025). Risk of serious infection with adalimumab in hidradenitis suppurativa compared with psoriasis. JAMA Dermatology. Advance online publication. https://doi.org/10.1001/jamadermatol.2025.2881

Keywords: adalimumab, hidradenitis suppurativa, psoriasis, infection risk, serious infection, JAMA Dermatology, sepsis, genitourinary infection, hospitalization, cohort study


Tags:    
Article Source : JAMA

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News